imatinib mesylate has been researched along with HbS Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, R; Gurkan, UA; Kalfa, T; Little, JA; Low, PS; Man, Y; Noomuna, P; Risinger, M; Seu, K; Sheik, DA; Turrini, FM; Wan, J; Zhou, S | 1 |
| Ericson, ME; Gupta, K; Gupta, M; Luk, K; Nguyen, J; Simone, DA; Vang, D; Vincent, L | 1 |
| Close, J; Lottenberg, R; Murphy, M; Rajasekhar, A | 1 |
| Bachmeyer, C; Garandeau, E; Lecomte, I; Lionnet, F; Stankovic Stojanovic, K; Thiolière, B | 1 |
4 other study(ies) available for imatinib mesylate and HbS Disease
| Article | Year |
|---|---|
Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Anion Exchange Protein 1, Erythrocyte; beta-Thalassemia; Cell Adhesion; Cell-Derived Microparticles; Drug Evaluation, Preclinical; Endothelium, Vascular; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes, Abnormal; Hemoglobin, Sickle; Humans; Imatinib Mesylate; Oxidative Stress; Oxygen; Phosphorylation; Phosphotyrosine; Plasma; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Sickle Cell Trait | 2020 |
Mast cell activation contributes to sickle cell pathobiology and pain in mice.
Topics: Anemia, Sickle Cell; Animals; Benzamides; Cells, Cultured; Cytokines; Ganglia, Spinal; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperalgesia; Hypoxia; Imatinib Mesylate; Leukocyte Count; Mast Cells; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Confocal; Neurogenic Inflammation; Nociceptors; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin; Substance P | 2013 |
Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence | 2011 |